Add BrightSurf on Google Email

New drug-delivery method offers promise in fight against neurodegenerative diseases

Researchers have developed a new method to deliver disease-fighting antibodies directly to the brain, using extracellular vesicles to bypass the blood-brain barrier. This approach shows potential in treating neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS, by improving the elimination of pathological proteins.

SourceUniversity of Ottawa·JournalNature Biomedical Engineering·TypeRandomized controlled/clinical trial·DateOct 15, 2026

Why autoantibodies may be linked to preterm birth risk in some women

Researchers at UCSF discovered a potential immune mechanism connecting maternal antibodies to premature birth, revealing a set of antibodies that appeared consistently once pregnancy began and reacted against a protein controlling inflammation. The study could lead to new ways of screening for preterm birth risk and new interventions t...

SourceUniversity of California - San Francisco·JournalNature Immunology·TypeExperimental study·DateOct 14, 2026

Poor antibody validation wastes millions of biological samples, but solutions exist

Two linked studies provide effective recommendations for publishers, funders, institutions, and manufacturers to address the widespread failure to validate research antibodies. The studies estimate that millions of animal and human tissue samples have been wasted globally without adequate validation. The consensus reached by an interna...

SourcePLOS·JournalPLOS Biology·TypeComputational simulation/modeling·DateOct 6, 2026

Recreating key features of the antibody factory in a dish

Scientists at the University of Osaka have developed a method to recreate human B cells with germinal center features using three immune signals, which closely match those found in human tonsils. This breakthrough could help improve vaccine-induced antibody responses and identify targets for autoimmune disease.

SourceImmunology Frontier Research Center (IFReC) - The University of Osaka·JournalScience Immunology·TypeExperimental study·DateSep 29, 2026

Korea University study uncovers how mRNA vaccination may broaden flu antibody responses

A Korea University study found that an mRNA-based influenza vaccine elicits a more diverse and broader serum antibody repertoire than traditional vaccines. This leads to greater binding and neutralizing breadth against diverse influenza strains, suggesting potential for broader, longer-lasting protection.

SourceKorea University College of Medicine·JournalNature Immunology·TypeExperimental study·DateSep 11, 2026

Immunity for the long haul: Why some antibodies are built to last

A team of researchers from the University of Osaka found that cells producing IgG1 antibodies have advantages over those producing IgM antibodies, including better antigen presentation, survival, and bone marrow migration. These advantages may lead to long-term immune protection and inform the development of more effective vaccines.

SourceImmunology Frontier Research Center (IFReC) - The University of Osaka·JournalScience Immunology·TypeExperimental study·DateSep 8, 2026

Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months

A phase 2 clinical trial found that a monoclonal antibody targeting interleukin-6 achieved sustained reductions in inflammation biomarkers for six months in patients with chronic kidney disease. The therapy, known as pacibekitug, was well-tolerated and showed favorable effects on additional biomarkers associated with cardiovascular risk.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·TypeRandomized controlled/clinical trial·DateAug 29, 2026

Scientists uncover that albumin is prevented from crossing the placenta – open opportunities for design of long-acting biologic medicines with limited fetal exposure

Researchers uncover the placenta distinguishes between antibodies and albumin, allowing for the design of long-acting biologic medicines with reduced fetal exposure. Fusion of IgG antibodies to albumin inhibits transport across the placenta, enabling the development of safer treatments during pregnancy.

Antibody clues could improve long COVID care and prognosis

A study by Okayama University researchers revealed that SARS-CoV-2 antibody levels can assess infection history, symptom severity, and cognitive complications in long COVID. The findings suggest that declining S-antibody levels may indicate a greater risk of neurological complications.

SourceOkayama University·JournalBritish Journal of Biomedical Science·TypeObservational study·DateJun 12, 2026

How cells fight infection from the inside

Scientists discovered a new way cells fight infection, using a method called antibody-directed xenophagy (ADX), which can digest bacteria and viruses inside infected cells. ADX is triggered by a protein called TRIM21, which flags invading pathogens for destruction.

SourceCell Press·JournalMolecular Cell·TypeExperimental study·DateJun 4, 2026

Your nose is a battlefield

Researchers at La Jolla Institute for Immunology discovered that FluMist can trigger an immune response directly in nasal tissue, training immune cells to recognize and fight influenza virus infection. This response stays in the upper airways and cannot be detected via blood samples.

SourceLa Jolla Institute for Immunology·JournalScience Translational Medicine·TypeExperimental study·DateApr 29, 2026

Building protection against infectious diseases with nanostructured vaccines

Researchers at the Wyss Institute developed DoriVac, a DNA nanotechnology-enabled vaccine platform that induces broad immunity against infectious viruses, including SARS-CoV-2, HIV, and Ebola. The platform produces potent antigen-specific immune responses and is more stable and easier to manufacture than traditional vaccine platforms.

SourceWyss Institute for Biologically Inspired Engineering at Harvard·JournalNature Biomedical Engineering·TypeExperimental study·DateMar 11, 2026

Why does the body deem some foods safe and others unsafe?

Researchers have identified three new proteins, called epitopes, that help the body determine 'safe' foods, aiding in food tolerance and allergy understanding. The epitopes were found in seed proteins from corn, wheat, and soybean, and interact with regulatory T cells to inform tolerance-or-rejection decisions.

SourceSalk Institute·JournalScience Immunology·DateMar 6, 2026

Gut microbe–derived butyrate activates immune cells to enhance vaccine efficacy

A study published in Microbiome found that gut microbiome-derived butyrate activates immune cells to enhance vaccine efficacy by promoting T follicular helper (Tfh) cell activity and mucosal antibody production. This discovery highlights the crucial role of gut environment regulation in controlling infections and enhancing vaccine resp...

Antibodies targeting immunoglobulin E Cε2 region as potential rapid anti-allergy therapy

Researchers identified Fab antibody fragments that target the IgE Cε2 domain, effectively stripping IgE from mast cells. The most potent Fab clones showed rapid efficacy in cellular assays and in vivo anaphylaxis models, demonstrating potential as a next-generation anti-allergy therapy.

SourceJuntendo University Research Promotion Center·JournalJournal of Allergy and Clinical Immunology·TypeExperimental study·DateJan 26, 2026

MIT researchers find new way to deliver antibodies that could make treatment much easier for patients

MIT researchers have found a new way to create solid particles of highly concentrated antibodies, suspended in a solution, which can be injected using a standard syringe. This advance could make antibody treatments more convenient and accessible for patients, particularly older people with difficulty visiting hospitals.

SourceMassachusetts Institute of Technology·JournalAdvanced Materials·DateDec 11, 2025